A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant

      Background: HER2/neu overexpression is highly associated with increased risk of cancer with poor prognosis which is especially seen in breast cancer along with some other cancer types such as gastric and ovarian cancers. Although HER2/neu overexpression is well characterized in various cancer types, no effective therapy is yet found against it.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect